Media headlines about Flex Pharma (NASDAQ:FLKS) have trended somewhat positive on Wednesday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Flex Pharma earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.8320476176287 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Flex Pharma (NASDAQ FLKS) traded up 1.74% during midday trading on Wednesday, hitting $3.51. The stock had a trading volume of 11,152 shares. Flex Pharma has a 12-month low of $3.28 and a 12-month high of $12.07. The company has a 50-day moving average price of $3.46 and a 200-day moving average price of $3.95. The company’s market cap is $60.67 million.

Flex Pharma (NASDAQ:FLKS) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.12. The company had revenue of $0.34 million during the quarter, compared to analyst estimates of $0.46 million. Flex Pharma had a negative return on equity of 64.15% and a negative net margin of 2,410.97%. Equities analysts anticipate that Flex Pharma will post ($2.34) EPS for the current year.

FLKS has been the subject of several research analyst reports. Zacks Investment Research downgraded Flex Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, May 23rd. Roth Capital initiated coverage on Flex Pharma in a report on Thursday, September 7th. They issued a “buy” rating and a $14.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Flex Pharma currently has a consensus rating of “Buy” and an average price target of $15.17.

TRADEMARK VIOLATION NOTICE: “Flex Pharma (FLKS) Earns Media Sentiment Score of 0.08” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/13/flex-pharma-flks-earns-media-sentiment-score-of-0-08.html.

About Flex Pharma

Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.

Insider Buying and Selling by Quarter for Flex Pharma (NASDAQ:FLKS)

Receive News & Stock Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related stocks with our FREE daily email newsletter.